Hepatitis C Drugs Whose Prices Drew Criticism Get FDA Warning
This article is for subscribers only.
Drugs that treat hepatitis C, whose high prices have previously sparked outrage, can in rare instances cause liver failure and other complications, the U.S. Food and Drug Administration said.
The FDA said it had received reports that drugs made by Gilead Sciences Inc., AbbVie Inc. and Merck & Co. can in some cases lead to worsening liver function in patients who already had moderate or severe liver damage, according to a statement Wednesday. The agency said the drugs remain safe for patients with mild liver disease.